IL1B and Arthritis: These cytokines mediate immunosuppressive effects in in vivo models of skin [138] and joint inflammation [139,140] by potentially reducing the expression of the Th17-associated cytokines [141] and attenuate the inflammation triggered by IL-1, IL-18, IL-36 and TLR-agonists [142,143].